TVRD
Tvardi Therapeutics, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Tvardi Therapeutics, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
Last report1 of 4 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
No changes.
No changes.
No thesis.
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Mar 31 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Tvardi Therapeutics, Inc.
0.80
pre 0.81 +0.50%
+7.34%
vs ±67.0% implied · ×0.11
shaded = implied · ▲▼ = realized
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; Tvardi Therapeutics, Inc.'s closest co-mover is outside that code.
Closest co-movers · 463d
CRNXCrinetics Pharmaceuticals×0.19r 0.28Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; Tvardi Therapeutics, Inc.'s closest co-mover is outside that code.
Closest co-movers · 463d
CRNXCrinetics Pharmaceuticals×0.19r 0.28| Manager | Value | % base | |
|---|---|---|---|
| Slate Path Capital | $1.3M | 31.61% | 0.00% |
| Vanguardindex-like | $654,326 | 15.46% | −0.09% |
| American Financial | $424,952 | 10.04% | 0.00% |
| UBS | $211,153 | 4.99% | +120.27% |
| Silvercrest | $191,965 | 4.54% | 0.00% |
| Manager | Value | % base | |
|---|---|---|---|
| Slate Path Capital | $1.3M | 31.61% | 0.00% |
| Vanguardindex-like | $654,326 | 15.46% | −0.09% |
| American Financial | $424,952 | 10.04% | 0.00% |
| UBS | $211,153 | 4.99% | +120.27% |
| Silvercrest | $191,965 | 4.54% | 0.00% |
Tall tick = annual report · Source: EDGAR
Bull1
Bear3
Largest filed tie
—
—
—
Expected move
No implied move.